Serum Institute looks to supply 25 million doses to Covax till December

Indian Govt to Get 25 Million doses of Covax from SII

Pune-based Serum Institute of India (SII) is expected to supply 25 million doses to the Covax facility till December, as it looks to resume supplies to the WHO-led Covax facility this month. Earlier in March, the government had imposed a hold on all major exports affecting the Covax deliveries.
SII CEO Adar Poonawalla said small exports will start soon. “I think January onwards there will be large exports to Covax because by then India will have more than enough vaccines. Already, there is more stock than what we are vaccinating. So, we will be in a very good situation. Combine that with the fact that other Indian vaccine manufacturers are also scaling up,”
The Covax facility was created last year to ensure Covid vaccines were made available around the world, with richer countries subsidising costs for poorer nations. The scheme hoped to distribute enough vaccines to protect at least 20% of the population in 92 low-or medium-income countries.

About SII

Serum Institute of India Pvt. Ltd. is now the world’s largest vaccine manufacturer by number of doses produced and sold globally (more than 1.5 billion doses) which includes Polio vaccine as well as Diphtheria, Tetanus, Pertussis, Hib, BCG, r-Hepatitis B, Measles, Mumps and Rubella vaccines. It is estimated that about 65% of the children in the world receive at least one vaccine manufactured by Serum Institute. Vaccines manufactured by the Serum Institute are accredited by the World Health Organization, Geneva and are being used in around 170 countries across the globe in their national immunization programs, saving millions of lives throughout the world.

Serum Institute of India is ranked as India’s No. 1 biotechnology company, manufacturing highly specialized life saving biologicals like vaccines using cutting edge genetic and cell based technologies, antisera and other medical specialties.

Serum Institute of India was founded in 1966 by Dr. Cyrus Poonawalla with the aim of manufacturing life-saving immuno-biologicals, which were in shortage in the country and imported at high prices. Thereafter, several life-saving biologicals were manufactured at prices affordable to the common man and in abundance, with the result that the country was made self-sufficient for Tetanus Anti-toxin and Anti-snake Venom serum, followed by DTP (Diphtheria, Tetanus and Pertussis) group of Vaccines and then later on MMR (Measles, Mumps and Rubella) group of vaccines.

 

The Philanthropic philosophy of the company still not only exists but has been proliferated to bring down the prices of newer vaccines such as Hepatitis-B vaccine, Combination vaccine etc., so that not only Indian’s, but the entire under-privileged children of the world are protected from birth onwards.

For more Information: Sign in Websites for Agrochemical & Pharmaceutical Databases:

Website : https://www.chemrobotics.com/ (Agrochemical Databases)

Website : https://chemroboticspharma.com/  (Pharmaceutical Databases)

 

 

Related posts

Patent Grant to Sumitomo Chemical for Agrochemical Combination Despite Pre-Grant Opposition

India Receives the First non-GM , Herbicide-Tolerant Rice Cultivars by The Indian Agricultural Research Institute (IARI)

Indian Farmers Fertiliser Cooperative Limited and Mitsubishi Corporation Launches Takibi (Flubendiamide 20% WG) Insecticide